NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 9th October

**Location:** Via Zoom and London Office

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Anna Pracz Present for all items
4. Dr Bushra Hasnie Present for all items
5. Dr Daniel Gallacher Present for all items
6. Dr Hatim Abdulhussein Items 1.1 to 4.2.2
7. Dr Natalia Kunst Present for all items
8. Dr Stuart Williams Present for all items
9. Dr Toby Smith Present for all items
10. Dr Warren Linley Present for all items
11. Gabriel Rogers  Present for all items
12. Lisa Attrill Present for all items
13. Nigel Westwood Present for all items
14. Stella O’Brien Present for all items
15. Tony Wootton Present for all items
16. Vanessa Danielson Items 1.1 to 4.2.2

NICE staff (key players) present

Emily Crowe, Associate Director Items 1.1 to 4.2.2

Jeremy Powell, Project Manager Items 1.1 to 4.2.2

Yelan Guo, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Luke Cowie, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Louise Jones, Administrator, Technology Appraisals Items 1.1 to 4.2.2

Rich Diaz, Associate Director Items 5.1 to 5.2.2

Vonda Murray, Project Manager Items 5.1 to 5.2.2

Joanna Richardson, Health Technology Assessment Adviser Items 5.1 to 5.2.2

Anna Willis, Health Technology Assessment Analyst Items 5.1 to 5.2.2

Madiha Adam, Health Technology Assessment Analyst Items 5.1 to 5.2.2

Wajeeha Asim, Administrator Items 5.1 to 5.2.2

External assessment group representatives present

Geoff Frampton, Southampton Health Technology Assessments Centre (SHTAC), University of Southampton Items 1.1 to 4.1.3

Neelam Kalita, Southampton Health Technology Assessments Centre (SHTAC), University of Southampton Items 1.1 to 4.1.3

Thenmalar Vadiveloo, Aberdeen HTA Group Items 5.1 to 5.1.3

Graham Scotland, Aberdeen HTA Group Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Abuk (Abby) Mabil, Patient expert, nominated by Muscular Dystrophy UK

Items 1.1 to 4.1.3

Maria Isabel da Silva Leite, Consultant Neurologist, Clinical expert nominated by UCB

Items 1.1 to 4.1.3

Gordon Cook, Professor of Haematology clinical expert, nominated by, UK Myeloma Society Items 5.1 to 5.1.3

Scott Purdon, Patient expert, nominated by Myeloma UK Items 5.1 to 5.1.3

Jon Missin, Patient expert, nominated by Myeloma UK Items 5.1 to 5.1.3

Peter Clark, NHS CDF clinical lead Items 5.1 to 5.2.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Kemi Gibson, Mark Tanner, Alistair Patton, Andrew Makin, David McAllister, Francis Drobniewski, Peter Wheatley Price, Rhiannon Owen, Veline L’Esperance.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 11th September 2024

1. **Appraisal of Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]**
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from UCB Pharma.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11096).
      3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Charles Crawley.
   2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
      1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus..
      2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11096>.

1. **Appraisal of Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026]** 
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pfizer.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10918).
      3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Charles Crawley.
   2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
      1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
      2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10918>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 13th November and will start promptly at 9am.